Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637 1653
This examiner grants 57% of resolved cases
Sarah Elizabeth Allen, working in Tech Center 1600 and Art Unit 1637, has 27 resolved cases. The allowance rate is 55.6 percent, which is a moderate success rate. This 55.6 percent rate indicates that more than half of the 27 cases result in a patent grant. Practitioners should expect a balanced examination process.
The interview lift is 50.0 percent, indicating that interviews are highly effective at resolving rejections. The median days to allowance is 1291, which is a long duration for reaching a grant. Practitioners should use interviews to capitalize on the 50.0 percent lift and improve the 55.6 percent allowance rate. The 1291-day timeline should be factored into the prosecution strategy. These metrics show that while the process is slow, direct communication with the examiner is a very successful tactic for securing a patent grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17763716 | METHODS AND SYSTEMS FOR PREPARING A NUCLEIC ACID CONSTRUCT FOR SINGLE MOLECULE CHARACTERISATION | Non-Final OA | Oxford Nanopore Technologies PLC |
| 17980883 | METHODS OF GENOME EDITING INCLUDING CONTROLLED OPENING OF CHROMATIN | Final Rejection | Wisconsin Alumni Research Foundation |
| 18271832 | RIBOZYME-ACTIVATED RNA CONSTRUCTS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 17604128 | PROTEIN TRANSLATIONAL CONTROL | Final Rejection | The Regents of the University of California |
| 18485930 | RESCUE STRATEGIES FOR BEST1 LOSS- AND GAIN-OF-FUNCTION MUTATIONS | Non-Final OA | University of Rochester |
| 18028183 | PRIME EDITING GUIDE RNAS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | Final Rejection | President and Fellows of Harvard College |
| 17905457 | RNA-GUIDED GENOME RECOMBINEERING AT KILOBASE SCALE | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18047685 | GENOMIC EDITING WITH SITE-SPECIFIC RETROTRANSPOSONS | Non-Final OA | Massachusetts Institute of Technology |
| 18269846 | CHEMICAL SUBSTANCE EVALUATION SYSTEM USING MULTICOLOR LIGHT-EMITTING CELLS | Non-Final OA | TOHOKU UNIVERSITY |
| 18563790 | CORRECTION OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS WITH ALL-IN-ONE ADENO-ASSOCIATED VIRUS-DELIVERED SINGLE-CUT CRISPR | Non-Final OA | The Board of Regents of The University of Texas System |
| 18459548 | ACYCLIC THREONINOL NUCLEIC ACID | Non-Final OA | AGC Inc. |
| 17717697 | GENE EDITING TO CORRECT ANEUPLOIDIES AND FRAME SHIFT MUTATIONS | Final Rejection | The Trustees of Columbia University in the City of New York |
| 17997312 | MODIFIED NUCLEIC ACIDS ENCODING ASPARTOACYLASE (ASPA) AND VECTOR FOR GENE THERAPY | Non-Final OA | Pfizer Inc. |
| 18709415 | GENE THERAPY FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS IIIA | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17917333 | COMPOSITIONS AND METHODS FOR IMPROVED SITE-SPECIFIC MODIFICATION | Non-Final OA | ASTRAZENECA AB |
| 18556180 | REDIRECTING RISC FOR RNA EDITING | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17668413 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 18486146 | M6A-COUPLED EFFECTOR PROTEIN EXPRESSION SYSTEM AND METHODS OF MAKING AND USING SAME | Non-Final OA | Duke University |
| 17635298 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | Non-Final OA | LONZA SALES AG |
| 17628881 | METHOD FOR REDUCING TOXICITY OF ANTISENSE NUCLEIC ACIDS | Final Rejection | TOKYO INSTITUTE OF TECHNOLOGY |
| 17817385 | HAIRPIN LOOP ENDED SELF-COMPLEMENTARY DOUBLE-STRANDED COVALENTLY CLOSED LINEAR DNA VECTOR, MANUFACTURING SYSTEM AND PROCESS, AND USES OF SAID RESULTING DNA VECTOR | Non-Final OA | SYTE.bio Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy